Skip to main content Back to Top
Advertisement

3/9/2020

Cyclosporine Oral Solution

Products Affected - Description

    • Sandimmune oral solution, Novartis, 100 mg/mL, 50 mL bottle, NDC 00078-0110-22
    • Neoral oral solution, Novartis, 100 mg/mL, 50 mL bottle, NDC 00078-0274-22
    • Cyclosporine oral solution, Teva, 100 mg/mL, 50 mL bottle, NDC 00591-2224-55
    • Cyclosporine oral solution, Teva, 100 mg/mL, 50 mL bottle, NDC 00172-7313-20

Reason for the Shortage

    • Teva has cyclosporine oral solution on shortage due to an active pharmaceutical ingredient delay.
    • Novartis did not provide a reason for the shortage.

Available Products

    • Gengraf oral solution, AbbVie, 100 mg/mL, 50 mL bottle, NDC 00074-7269-50

Estimated Resupply Dates

    • Novartis has Neoral oral solution on back order and the company cannot estimate a release date. A limited emergency supply is available for drop ship.
    • Novartis has Sandimmune oral solution on back order and the company cannot estimate a release date. A limited emergency supply is available for drop ship.
    • Teva has cyclosporine modified oral solution on back order and the company estimates a release date of early-April 2020.

Updated

Updated March 9, 2020 by Leslie Jensen, PharmD, Drug Information Specialist. Created September 24, 2019 by Rachael Freeman, PharmD, BCPS. © 2020, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.